Angela D Angelo

List of Publications by Citations

Source: https://exaly.com/author-pdf/8621517/angela-dangelo-publications-by-citations.pdf

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers2,961
citations29
h-index49
g-index130
ext. papers3,358
ext. citations4.4
avg, IF5.07
L-index

#	Paper	IF	Citations
124	Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2005 , 25, 1032-7	9.4	320
123	Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. <i>Archives of Neurology</i> , 2005 , 62, 1734-6		163
122	Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. <i>Journal of Hypertension</i> , 2005 , 23, 1725-9	1.9	142
121	Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2006 , 13, 227-31		107
120	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 887-95	12.7	93
119	A role for quercetin in coronavirus disease 2019 (COVID-19). Phytotherapy Research, 2021, 35, 1230-12	36 6.7	78
118	Adipocytokine levels in obese and non-obese subjects: an observational study. <i>Inflammation</i> , 2013 , 36, 914-20	5.1	71
117	Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. <i>Hypertension Research</i> , 2006 , 29, 849-56	4.7	70
116	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 475-82	5.4	64
115	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. <i>Heart and Vessels</i> , 2007 , 22, 361-70	2.1	55
114	Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. <i>Clinical</i>	3.5	55
113	High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. <i>Journal of the American Geriatrics Society</i> , 2006 , 54, 1149-50	5.6	55
112	Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. <i>Atherosclerosis</i> , 2006 , 186, 140-5	3.1	54
111	Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. <i>Hypertension Research</i> , 2007 , 30, 387-94	4.7	52
110	Increased urinary NO2-/NO3- and cyclic guanosine monophosphate levels in patients with Bartter © syndrome: relationship to vascular reactivity. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 784-9	7.4	48
109	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. Journal of Clinical Lipidology, 2012 , 6, 553-64	4.9	43
108	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , 2010 , 57, 777-86	2.9	42

(2010-2005)

107	Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. <i>Hypertension Research</i> , 2005 , 28, 917-24	4.7	42	
106	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , 2011 , 651, 240-50	5.3	41	
105	Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. <i>Journal of Hypertension</i> , 2010 , 28, 111-8	1.9	39	
104	A Clinical Trial about a Food Supplement Containing Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	39	
103	Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1495-506	5.4	37	
102	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , 2009 , 24, 204-10	2.1	37	
101	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1973-83	2.5	33	
100	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , 2009 , 32, E124-32	0.9	32	
99	Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , 2016 , 42, 316-22	6.1	32	
98	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , 2011 , 34, 145-51	4.7	31	
97	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , 2009 , 25, 607-15	2.5	30	
96	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. <i>Internal Medicine</i> , 2010 , 49, 1717-25	1.1	29	
95	Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007 , 14, 45-51		29	
94	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 421-9	12.7	28	
93	Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. <i>Scientific World Journal, The</i> , 2013 , 2013, 584504	2.2	25	
92	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1971-82	4	25	
91	Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , 2015 , 239, 87-92	3.1	24	
90	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , 2010 , 80, 110-5	3.7	24	

89	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015 , 108, 329-35	7.4	23
88	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 957-67	12.7	23
87	Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. <i>Internal Medicine</i> , 2013 , 52, 2179-87	1.1	23
86	Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , 2011 , 25, 642-51	3.1	22
85	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , 2010 , 79, 144-9	3.7	22
84	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markErs in the progreSsion of diabeteS in obese paTieNts (The RESISTIN trial). <i>Cytokine</i> , 2020 , 127, 154947	4	22
83	Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation. <i>Disease Markers</i> , 2013 , 35, 135-40	3.2	21
82	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , 2010 , 33, 790-5	4.7	21
81	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2581-91	4	21
80	Effects of nateglinide and glibenclamide on prothrombotic factors in naWe type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. <i>Internal Medicine</i> , 2007 , 46, 18	3 7 -46	20
79	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. <i>Clinical Therapeutics</i> , 2007 , 29, 602-10	3.5	20
78	The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , 2016 , 35, 1091-5	5.9	19
77	Long-term effects of a multidisciplinary treatment of uncomplicated obesity on carotid intima-media thickness. <i>Obesity</i> , 2011 , 19, 1187-92	8	19
76	Berberis aristata/Silybum marianum fixed combination (Berberol([])) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , 2015 , 22, 231-7	6.5	18
75	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and Etell function. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2433-42	4	18
74	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , 2010 , 33, 209-13	4.7	18
73	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60@ study. <i>Metabolism: Clinical and Experimental</i> , 2009 , 58, 1059-66	12.7	18
72	Molecular biology-based assessment of vitamin E-coated dialyzer effects on oxidative stress, inflammation, and vascular remodeling. <i>Artificial Organs</i> , 2011 , 35, E33-9	2.6	17

71	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , 2011 , 113, 950-960	3	16
70	Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11, 159-69	8.1	16
69	Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. <i>Archives of Medical Research</i> , 2008 , 39, 412-9	6.6	15
68	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15, 214-22	8.1	14
67	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , 2009 , 63, 723-33	7.5	14
66	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2008 , 57, 1552-7	12.7	14
65	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , 2015 , 100, 127-34	10.2	13
64	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 66	2.3	13
63	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , 2018 , 42, 75-82	6.5	12
62	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , 2015 , 38, 690-4	4.7	12
61	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	12
60	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 1113-22	2.2	12
59	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , 2020 , 73, 110700	4.8	12
58	Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. <i>International Journal of Molecular Medicine</i> , 2004 , 13, 243-7	4.4	12
57	Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007 , 14, 175-83		11
56	Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk. <i>European Psychiatry</i> , 2006 , 21, 129-33	6	11
55	Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients. <i>American Journal of Nephrology</i> , 2004 , 24, 221-9	4.6	11
54	Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. <i>Clinica Chimica Acta</i> , 2004 , 350, 159-65	6.2	11

53	Apolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer@ disease. <i>Neuroscience Letters</i> , 2004 , 357, 45-8	3.3	11
52	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2010 , 13, 378-90	3.4	10
51	Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. <i>Internal Medicine</i> , 2009 , 48, 265-71	1.1	10
50	Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglicemic patients. <i>Phytotherapy Research</i> , 2019 , 33, 791-797	6.7	9
49	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , 2015 , 766, 31-6	5.3	9
48	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 653-661	3.4	9
47	Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 3647-3655	4.4	9
46	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , 2012 , 59, 611-9	2.9	9
45	Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. <i>Mediators of Inflammation</i> , 2012 , 2012, 874149	4.3	9
44	Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. <i>Clinical Drug Investigation</i> , 2006 , 26, 529-39	3.2	9
43	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. <i>Blood Pressure</i> , 2009 , 18, 111-6	1.7	8
42	Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. <i>Journal of the American Society of Hypertension</i> , 2013 , 7, 32-9		7
41	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2015 , 14, 95	8.7	7
40	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , 2015 , 47, 47-52	1.5	7
39	Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47, 508-12	3.1	7
38	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 845-859	1.9	7
37	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , 2017 , 92, 75-79	4	6
36	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1391-1399	2.9	5

(2015-2019)

35	Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 1861-1865	3.4	5
34	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. <i>Inflammation</i> , 2014 , 37, 154-62	5.1	5
33	Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 422-8		5
32	Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. <i>Clinical and Experimental Hypertension</i> , 2013 , 35, 301-7	2.2	5
31	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial. <i>Pharmacotherapy</i> , 2015 , 35, 983-90	5.8	5
30	Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). <i>Endocrine Journal</i> , 2009 , 56, 571-8	2.9	5
29	The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005 , 1687, 1-10	5	5
28	Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects. <i>BMC Cardiovascular Disorders</i> , 2003 , 3, 12	2.3	5
27	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , 2021 , 8, 605691	4.9	5
26	Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 5367-	5 3// 4	4
25	Diazepam as an oral hypnotic increases nocturnal blood pressure in the elderly. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 463-468	4.8	4
24	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	4
23	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 621-9	4.1	4
22	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy,</i> 2018 , 12, 2611-2616	4.4	4
21	Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy. <i>Archives of Medical Science</i> , 2017 , 13, 550-557	2.9	3
20	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1791-1795	7	3
19	Ambulatory 24-h ECG monitoring and cardiovascular autonomic assessment for the screening of silent myocardial ischemia in elderly type 2 diabetic hypertensive patients. <i>Heart and Vessels</i> , 2017 , 32, 507-513	2.1	3
18	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , 2015 , 5, 12603	4.9	3

17	Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3219	7.5	3
16	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , 2020 , 1-10	1.7	2
15	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , 2021 , 12, 582556	8.4	2
14	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , 2019 , 11,	6.7	2
13	Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre-diabetes. <i>Phytotherapy Research</i> , 2020 , 34, 1377-1384	6.7	2
12	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , 2018 , 14, 760-765	2.9	1
11	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1136-41	3.2	1
10	Effects of a nutraceutical combination of monacolin, Ebryzanol and Elaminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , 2019 , 15, 792-796	2.9	1
9	Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimcina), White Mulberry and Chromium Picolinate in Nondiabetic Subects with Dysglycemia: A Randomized Trial. <i>Life</i> , 2021 , 11,	3	1
8	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , 2021 , 17, 1087-1092	2.9	O
7	Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 191-195	1.7	О
6	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, L. and , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction <i>Frontiers in Endocrinology</i> , 2022 ,	5.7	O
5	Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1248	3.2	
4	Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39. <i>Journal of the American Society of</i>		
3	Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 822		
2	Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. <i>European Medical Journal Diabetes</i> ,70-78	1	
1	Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33].	5.1	